Bulevirtide‐based treatment strategies for chronic hepatitis delta: A review

• Published in: Journal of viral hepatitis Vol. 30; no. S1; pp. 26 - 32
• Main Authors: Degasperi, Elisabetta, Anolli, Maria Paola, Lampertico, Pietro
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.04.2023
• Subjects: Adult; Antiviral Agents - adverse effects; Antiviral drugs; bulevirtide; chronic delta hepatitis; Cirrhosis; Clinical trials; combined response; entry inhibitor; HDV; HDV‐RNA; Hepatitis; Hepatitis Delta Virus; Hepatitis, Chronic - drug therapy; Humans; Liver diseases; Patients; Treatment Outcome; virological response; entry inhibitor; bulevirtide; virological response; chronic delta hepatitis; HDV-RNA; combined response; HDV; cirrhosis

Chronic hepatitis Delta (CHD) is a rare and severe form of chronic viral hepatitis. Until recently, the only therapeutic approach has been the off‐label use of a 48 weeks course of PegInterferon alpha (PegIFNα), that was characterized by suboptimal efficacy and burdened by significant side effects t...